Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H11NO.C4H6O4 |
| Molecular Weight | 255.2671 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CCC1=NC(C)=CC=C1O
InChI
InChIKey=IKMNOGHPKNFPTK-UHFFFAOYSA-N
InChI=1S/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)
| Molecular Formula | C8H11NO |
| Molecular Weight | 137.179 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C4H6O4 |
| Molecular Weight | 118.088 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Emoxypine (ethylmethylhydroxypyridine) succinate (MEXIDOL®) is a 3-hydroxypyridine derivative which is quite similar in structure to Vitamin B6 (pyridoxine). The most important components of the mechanism of action of Mexidol® are its antioxidant and membranotropic effects, the ability to modulate functioning of receptors and membrane-bound enzymes, restore a neurotransmitter balance. Due to its mechanism of action Mexidol® has a wide range of pharmacological effects, realized on at least two levels – neuronal and vascular. It has antihypoxic, anti-ischemic, neuroprotective, nootropic, vegetotrophic, anti-stress, anxiolytic, anticonvulsant, anti-alcohol, cardioprotective, anti-atherogenic, geroprotective and other actions. Under the action of Mexidol®, it is observed an improvement in cerebral circulation and microcirculation. Emoxypine is distributed in Russia but it is widely unknown in other regions.
Originator
Curator's Comment: In early 1980s, in State Institution Research Institute of Pharmacology of RAMS, by L.D. Smirnov and V.I. Kuzmin, 2-ethyl-6-methyl-3-hydroxypyridine succinate was synthesized, and under supervision of Academician of RAMS A.V. Valdman, its pharmacological effects were found, the mechanism of action was studied, preclinical studies on toxicology and pharmacokinetics were carried out, the Mexidol® trademark was identified, the drug was registered in the USSR Ministry of Healthcare, the first clinical trials and introduction of the preparation into medical practice were carried out.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Model corasol-induced seizures are followed by increase of nitric oxide generation and are abolished by mexidol and alpha-tocopherol]. | 2003 Jul-Aug |
|
| [Effect of low intensity laser light in the red range on macrophage superoxide dismutase activity]. | 2003 May-Jun |
|
| [Cytogenetic changes of the bone marrow in massive blood loss and their correction with mexidol]. | 2003 Nov-Dec |
|
| [Correction by 2-ethyl-6-methyl-3-hydroxypyridine succinate of the hepatotoxyc, caused at rats introduction tuberculostatics]. | 2004 |
|
| [Xerostomia. Diagnosis and treatment]. | 2004 |
|
| [Efficacy of cytoprotective agent Mexicor in urgent cardiology]. | 2004 |
|
| [Effect of phenyl-tert-butylnitrone, mexidol and nooglutil on the ischemic lesion zone and memory in rats following middle cerebral artery occlusion]. | 2004 Jan-Feb |
|
| [Effect of hydroxymethylethylpyridine succinate on the cardiac electrophysiological and hemodynamic parameters during experimental thoracotomy and acute myocardial ischemia]. | 2004 May-Jun |
|
| [Effect of typical and atypical anxiolytics on the behavior and electrophysiological parameters of rats with model cerebrovascular pathology]. | 2004 Nov-Dec |
|
| [Investigation of the effects of mexidol in escapable and inescapable emotional stress in inbred BALB/C and C57BL/6 mice]. | 2004 Nov-Dec |
|
| [Protective effect of activators of biological oxidation in nitrite intoxication in rats]. | 2005 |
|
| [Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia]. | 2005 |
|
| [Results of application of synthetic antioxidants in treatment of patients with destructive pancreatitis]. | 2005 |
|
| Antihypoxic and antinecrotic effect of mexidol in skin ischemia. | 2005 Feb |
|
| [Biotransformation of mexidol in inbred BALB/C and C57BL/6 mice]. | 2005 Mar-Apr |
|
| [Antinecrotic and antiischemic effect of mexidol and trental in ischemia of the skin graft]. | 2005 May |
|
| [Mexidol in treatment of children with generalized epilepsy and febrile seizures]. | 2005 May |
|
| The effects of Mexidol on the acquisition of food-related conditioned reflexes and synaptic ultrastructure in field CA1 of the rat hippocampus after single acoustic stimuli with ultrasonic components. | 2005 May |
|
| [Mexidol corrects model post-reanimation changes in cerebral lipid metabolism]. | 2005 May-Jun |
|
| [Antihypoxant activity and mechanisms of action of some natural and synthetic compounds]. | 2005 Sep-Oct |
|
| [Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis]. | 2005 Sep-Oct |
|
| [The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke]. | 2006 |
|
| [Efficacy of the use of antioxidant preparation mexidol in comprehensive treatment of inflammatory diseases of parodontium]. | 2006 |
|
| [The use of mexidol in urgent treatment of drug addiction]. | 2006 |
|
| [Mexidol in combined treatment of acute pancreatitis]. | 2006 |
|
| [Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy]. | 2006 |
|
| [Lipid reducing and antioxidant action of mexicor in patients with diabetes mellitus type 2]. | 2006 |
|
| [Antioxidants in complex treatment of Parkinson's disease]. | 2006 |
|
| [Neurometabolic therapy of diabetic neuropathy]. | 2006 |
|
| [Complex therapy of acute and exacerbated chronic nonspecific parotitis including mexidol and non-coherent infrared therapy]. | 2006 |
|
| [The use of mexidol in psychiatric practice]. | 2006 |
|
| [Neureprotective drugs efficiency in patients with chronic tension headaches]. | 2006 |
|
| [Antioxidant activity of inhibitors of free radical reactions in the dressing materials for wound healing]. | 2006 Jan-Feb |
|
| [Antistressor and analgesic effects of mexidol, diazepam, paracetamol, and their combinations]. | 2006 Jul-Aug |
|
| Effect of mexidol and nitroglycerine on iron-sulfur centers, cytochrome P-450, and nitric oxide formation in liver tissue of experimental animals. | 2006 Oct |
|
| [The efficacy of oxynicotinic acid a nd its derivatives in respect of functional activity of hepatocytes during acute toxic hepatopathy]. | 2006 Oct-Dec |
|
| [The effectiveness of ascorbic acid and emoxipin in treatment of infiltrative pulmonary tuberculosis]. | 2007 |
|
| [The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents]. | 2007 |
|
| [Influence of gel Metrogil Denta and curative toothpaste Mexidol Dent activ on indices of parodontal status and lipid peroxidation in patients with chronic generalized catarrhal gingivitis]. | 2007 |
|
| [The influence of 3-oxypyridine antioxidants on depression in patients with diabetes mellitus]. | 2007 |
|
| Lymphotropic effect of dimephosphon, mexidol, and ketorolac is realized via activation of the lymphangion and stimulation of lymph formation. | 2007 Apr |
|
| [The effect of rubomycin, mexidol and emoxypine on some metabolic indexes and the proccess of spontaneous metastasis under conditions of experimental neoplasia]. | 2007 Jan-Feb |
|
| [Acute radiation sickness in experiment. Efficacy of mexidol]. | 2007 Jul-Sep |
|
| Efficacy of neuroprotectors in patients with tension headaches. | 2007 Jun |
|
| [Effect of mexidol on hemopoietic system in conditions of an emotional stress after exposure to ionizing radiation]. | 2007 Mar-Apr |
|
| [Combined action of mexidol and non-narcotic analgesics on pain thresholds and emotional stress behavior in animals]. | 2007 Mar-Apr |
|
| [Pharmacological correction of neuronal damage in sensomotor zone of frontal cortex under conditions of experimental cerebral blood flow pathology]. | 2007 Nov-Dec |
|
| [The regulatory effect of mexidol on the hemoglobin level under acute stress conditions]. | 2007 Sep-Oct |
|
| [Experience with complex treatment for childhood amblyopia]. | 2008 Jan-Feb |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 01:29:45 UTC 2023
by
admin
on
Thu Jul 06 01:29:45 UTC 2023
|
| Record UNII |
2R985002CT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2R985002CT
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY | |||
|
127464-43-1
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY | |||
|
DTXSID30155577
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY | |||
|
100000128270
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY | |||
|
122298
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY | |||
|
C070020
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY | |||
|
SUB35088
Created by
admin on Thu Jul 06 01:29:45 UTC 2023 , Edited by admin on Thu Jul 06 01:29:45 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |